Principles of antibacterial dosing in continuous renal replacement therapy

Objectives: To outline the concepts involved in optimizing antibacterial dosing in critically ill patients with acute renal failure undergoing continuous renal replacement therapy (CRRT), provide a strategy for optimizing dosing, and summarize the data required to implement the strategy. Data Sources: MEDLINE search from February 1986 to 2008. Data Extraction and Synthesis: Optimal dosing of antibacterials is dependent on achieving pharmacokinetic targets associated with maximal killing of bacteria and improved outcomes. The initial dose is dependent on the volume of distribution. Maintenance doses are dependent on clearance. Both should be adjusted according to the pharmacokinetic target associated with optimal bacterial killing, when known. The volume of distribution of some antibacterials is altered by critical illness or acute renal failure or both. Clearance by CRRT is dependent on the dose and mode of CRRT and the sieving or saturation coefficient of the drug. Both sieving and saturation coefficient are related to the plasma protein binding and thus may be altered in renal failure. Conclusions: Appropriate dose calculation requires knowledge of the pharmacokinetic target and the usual minimum inhibitory concentration of the suspected organism in the patient's locality (or if unavailable, the break point for the organism), published pharmacokinetic data (volume of distribution, non-CRRT clearance) on critically ill patients receiving CRRT (which may differ substantially from noncritically ill patients or those without renal failure), the sieving or saturation coefficient of the relevant drug in critically ill patients, the dose and mode of CRRT being used, and the actual dose of CRRT that is delivered. This large number of variables results in considerable inter- and intrapatient heterogeneity in dose requirements. This article provides basic principles and relevant data to guide the clinician in prescribing individualized dosing regimes.

[1]  H. Bruch,et al.  Pharmacokinetics of Levofloxacin During Continuous Venovenous Hemodiafiltration and Continuous Venovenous Hemofiltration in Critically Ill Patients , 2002, Pharmacotherapy.

[2]  J. Donauer,et al.  Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. , 1999, Kidney international. Supplement.

[3]  H. Iwasaka,et al.  Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). , 2010, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[4]  P. Viale,et al.  Antimicrobial Therapy in Critically Ill Patients , 2005, Clinical pharmacokinetics.

[5]  S. Uchino,et al.  The epidemiology of acute renal failure in the world , 2006, Current opinion in critical care.

[6]  K. Ratheiser,et al.  Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. , 2002, The Journal of antimicrobial chemotherapy.

[7]  P. Marik,et al.  A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. , 1991, The Journal of antimicrobial chemotherapy.

[8]  F. Pea,et al.  Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. , 2001, Therapeutic drug monitoring.

[9]  P. Lemberger,et al.  Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration , 2001, Intensive Care Medicine.

[10]  E. Kuijper,et al.  Once versus thrice daily gentamicin in patients with serious infections , 1993, The Lancet.

[11]  K. Stoeckel,et al.  Pharmacokinetics of Ceftriaxone in Patients Undergoing Continuous Veno‐Venous Hemofiltration , 1996, Journal of clinical pharmacology.

[12]  K. Ikawa,et al.  Pharmacokinetic modeling and dosage adaptation of biapenem in Japanese patients during continuous venovenous hemodiafiltration , 2008, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[13]  K. Ko,et al.  High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study) , 2004, Antimicrobial Agents and Chemotherapy.

[14]  W. Jaeger,et al.  How to Calculate Clearance of Highly Protein-Bound Drugs during Continuous Venovenous Hemofiltration Demonstrated with Flucloxacillin , 2003, Kidney and Blood Pressure Research.

[15]  M. Reng,et al.  Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy , 2008, Intensive Care Medicine.

[16]  T. Buclin,et al.  Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients , 2003, Journal of clinical pharmacology.

[17]  K. Chow,et al.  Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[18]  D. Paterson,et al.  Antibiotic resistance—What’s dosing got to do with it? , 2008, Critical care medicine.

[19]  J. Rello,et al.  Influence of Renal Function on the Pharmacokinetics of Piperacillin/Tazobactam in Intensive Care Unit Patients During Continuous Venovenous Hemofiltration , 2005, Journal of clinical pharmacology.

[20]  E. Abraham,et al.  Pharmacokinetics and Pharmacodynamics of Imipenem during Continuous Renal Replacement Therapy in Critically Ill Patients , 2005, Antimicrobial Agents and Chemotherapy.

[21]  P. Palevsky,et al.  Determinants of Ceftazidime Clearance by Continuous Venovenous Hemofiltration and Continuous Venovenous Hemodialysis , 2000, Antimicrobial Agents and Chemotherapy.

[22]  G. Karth,et al.  Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. , 2005, The Journal of antimicrobial chemotherapy.

[23]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[24]  R. Bellomo,et al.  Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[25]  C. Gomersall,et al.  The adsorption of vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters. , 2007, Artificial organs.

[26]  J. Roberts,et al.  Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration , 2010, Antimicrobial Agents and Chemotherapy.

[27]  T. Schroeder,et al.  Pharmacokinetics of Antibiotics During Continuous Renal Replacement Therapy , 2005 .

[28]  Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function , 2005 .

[29]  Jian Li,et al.  Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration , 2005, Antimicrobial Agents and Chemotherapy.

[30]  O. Cars,et al.  Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis , 1991 .

[31]  M. Vos,et al.  Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD) , 2005, Intensive Care Medicine.

[32]  R. Bellomo,et al.  Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution , 2002, Intensive Care Medicine.

[33]  R. Beale,et al.  Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno‐venous hemofiltration or hemodiafiltration , 2000, Critical care medicine.

[34]  S. Brunet,et al.  Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  K. Rodvold.  Pharmacodynamics of Antiinfective Therapy: Taking What We Know to the Patient's Bedside , 2001, Pharmacotherapy.

[36]  H. Losert,et al.  Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. , 2001, The Journal of antimicrobial chemotherapy.

[37]  R. Farinotti,et al.  Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. , 1994, The Journal of antimicrobial chemotherapy.

[38]  D. Cutler,et al.  Gentamicin clearance during continuous arteriovenous hemodiafiltration , 1992, Critical care medicine.

[39]  J. Parrillo,et al.  The pathophysiology of septic shock. , 2009, Critical care clinics.

[40]  D. Nicolau.  Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling , 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[41]  L. Lacey,et al.  Pharmacokinetics of cefuroxime and ceftazidime in patients with acute renal failure treated by continuous arteriovenous haemodialysis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  J. Roberts,et al.  Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? , 2010, International journal of antimicrobial agents.

[43]  E. Rochard,et al.  Amikacin pharmacokinetics during continuous veno-venous hemofiltration. , 1991, Critical care medicine.

[44]  A. Vinks,et al.  Continuous infusion of beta-lactams , 2007, Current opinion in critical care.

[45]  B. Bruguerolle,et al.  Moxifloxacin Penetration in Bronchial Secretions of Mechanically Ventilated Patients with Pneumonia , 2004, Antimicrobial Agents and Chemotherapy.

[46]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[47]  W. Macias,et al.  Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance , 1991, Clinical pharmacology and therapeutics.

[48]  Sum Lam,et al.  Cefepime Neurotoxicity: Case Report, Pharmacokinetic Considerations, and Literature Review , 2006, Pharmacotherapy.

[49]  R. Bellomo,et al.  Principles of solute clearance during continuous renal replacement therapy , 1998 .

[50]  O. Cars,et al.  Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration. , 1988, Clinical nephrology.

[51]  D. Fish,et al.  Pharmacokinetics of Cefepime during Continuous Renal Replacement Therapy in Critically Ill Patients , 2001, Antimicrobial Agents and Chemotherapy.

[52]  J. Roberts,et al.  Antibacterial Dosing in Intensive Care , 2006, Clinical pharmacokinetics.

[53]  J. Meulenbelt,et al.  Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration , 2000, Critical care medicine.

[54]  F. Hawker.  Liver Dysfunction in Critical Illness , 1991, Anaesthesia and intensive care.

[55]  D. Fish,et al.  Pharmacokinetics of Levofloxacin and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ill Patients , 2001, Antimicrobial Agents and Chemotherapy.

[56]  R. Quigley,et al.  Clearance of Ticarcillin‐Clavulanic Acid by Continuous Venovenous Hemofiltration in Three Critically Ill Children, Two With and One Without Concomitant Extracorporeal Membrane Oxygenation , 1996, Pharmacotherapy.

[57]  J. Pedraz,et al.  Meropenem and Continuous Renal Replacement Therapy: In Vitro Permeability of 2 Continuous Renal Replacement Therapy Membranes and Influence of Patient Renal Function on the Pharmacokinetics in Critically Ill Patients , 2005, Journal of clinical pharmacology.

[58]  S. Tett,et al.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. , 2004, British journal of clinical pharmacology.

[59]  I. Bakker-Woudenberg,et al.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin inKlebsiella pneumoniae pneumonia and septicemia in leukopenic rats , 1989, European Journal of Clinical Microbiology and Infectious Diseases.

[60]  P. Schollmeyer,et al.  Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. , 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[61]  C. Gomersall,et al.  Adsorption of Amikacin, a Significant Mechanism of Elimination by Hemofiltration , 2007, Antimicrobial Agents and Chemotherapy.

[62]  Brian T. Tsuji,et al.  Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin , 2007, Antimicrobial Agents and Chemotherapy.

[63]  A. D. Pont.  Extracorporeal treatment of intoxications. , 2007 .

[64]  E. Hassan,et al.  Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients , 1987, Antimicrobial Agents and Chemotherapy.

[65]  P. Marik,et al.  The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. , 1991, The Journal of antimicrobial chemotherapy.

[66]  C. Ronco,et al.  Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[67]  Thaddeus H. Grasela,et al.  Pharmacodynamics of Fluoroquinolones againstStreptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections , 2001, Antimicrobial Agents and Chemotherapy.

[68]  P. Ferdinande,et al.  Pharmacokinetics of continuous renal replacement therapy , 1995, Intensive Care Medicine.

[69]  P. Palevsky,et al.  Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[70]  K. Wolter,et al.  Pharmacokinetics and dosage recommendations of teicoplanin in patients treated by continuous veno-venous haemodialysis (CVVHD) , 2004, European Journal of Clinical Pharmacology.

[71]  T. Schroeder,et al.  Pharmacokinetics of Meropenem in Critically Ill Patients with Acute Renal Failure Treated by Continuous Hemodiafiltration , 1998, Antimicrobial Agents and Chemotherapy.

[72]  C. Seger,et al.  Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration. , 2010, International journal of clinical pharmacology and therapeutics.

[73]  J. Pedraz,et al.  Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. , 2005, Clinical therapeutics.

[74]  J. Pedraz,et al.  In vitro AN69 and Polysulphone Membrane Permeability to Ceftazidime and in vivo Pharmacokinetics during Continuous Renal Replacement Therapies , 2007, Chemotherapy.

[75]  A. Markham,et al.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. , 1996, Drugs.

[76]  H. Bruining,et al.  Experience with a once-daily dosing program of aminoglycosides in critically ill patients , 2002, Intensive Care Medicine.

[77]  T. Oh,et al.  Intermittent bolus dosing of ceftazidime in critically ill patients. , 1997, Journal of Antimicrobial Chemotherapy.

[78]  D. Burgess.  Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. , 1999, Chest.

[79]  J. Lötsch,et al.  Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration , 1999, Clinical pharmacology and therapeutics.

[80]  W. Bennett,et al.  Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects , 1988, Clinical pharmacology and therapeutics.

[81]  P. Daley,et al.  Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration , 2001, Intensive Care Medicine.

[82]  T. Mazzei,et al.  Pharmacokinetic Evaluation of Meropenem and Imipenem in Critically Ill Patients with Sepsis , 2005, Clinical pharmacokinetics.

[83]  P. Palevsky,et al.  Determinants of Ceftriaxone Clearance by Continuous Venovenous Hemofiltration and Hemodialysis , 2000, Pharmacotherapy.

[84]  C. Gomersall,et al.  The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. , 2001, The Journal of antimicrobial chemotherapy.

[85]  W. Jaeger,et al.  Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. , 2004, The Journal of antimicrobial chemotherapy.

[86]  J. Bertrand,et al.  Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation , 2006, Critical care.

[87]  W. Craig,et al.  In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid) , 2002, Antimicrobial Agents and Chemotherapy.

[88]  G. Drusano,et al.  Back to the future: using aminoglycosides again and how to dose them optimally. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  A. MacGowan,et al.  The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. , 1997, The Journal of antimicrobial chemotherapy.

[90]  R. Schrier,et al.  Acute renal failure and sepsis. , 2004, The New England journal of medicine.

[91]  G. Drusano,et al.  Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria , 1999, Antimicrobial Agents and Chemotherapy.

[92]  C. Gomersall,et al.  The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin. , 2004, International journal of antimicrobial agents.

[93]  D. Treacher,et al.  Management of acute renal failure on the intensive care unit. , 2002, Clinical medicine.

[94]  R. Wise,et al.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin , 1980, Antimicrobial Agents and Chemotherapy.

[95]  D. Levine,et al.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  G. Drusano,et al.  Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity , 1999, Antimicrobial Agents and Chemotherapy.

[97]  R. Bellomo,et al.  Early acute kidney injury and sepsis: a multicentre evaluation , 2008, Critical care.

[98]  J. Turnidge.  The Pharmacodynamics of β-Lactams , 1998 .

[99]  D. Fliser,et al.  Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis* , 2006, Critical care medicine.

[100]  E. Selimoğlu,et al.  Aminoglycoside-induced ototoxicity. , 2007, Current pharmaceutical design.

[101]  G L Drusano,et al.  Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. , 1998, JAMA.

[102]  G. Drusano.  Infection Site Concentrations: Their Therapeutic Importance and the Macrolide and Macrolide‐Like Class of Antibiotics , 2005, Pharmacotherapy.

[103]  G L Drusano,et al.  Prevention of resistance: a goal for dose selection for antimicrobial agents. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[104]  J. Bugge.  Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients , 2001, Acta anaesthesiologica Scandinavica.

[105]  Roger Williams,et al.  The systemic inflammatory response syndrome in acute liver failure , 2000, Hepatology.

[106]  R Bellomo,et al.  Continuous renal replacement therapy in critically ill patients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[107]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[108]  W. Salzer,et al.  Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[109]  R. Bellomo,et al.  Pharmacological Principles of Antibiotic Prescription in the Critically Ill , 2002, Anaesthesia and intensive care.

[110]  P. Viale,et al.  Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[111]  G. Eliopoulos,et al.  The Sanford guide to antimicrobial therapy , 2010 .

[112]  W. Craig,et al.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. , 1989, The Journal of infectious diseases.

[113]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[114]  H. Dieterich,et al.  Correlation of Meropenem Plasma Levels with Pharmacodynamic Requirements in Critically Ill Patients Receiving Continuous Veno-Venous Hemofiltration , 2003, Chemotherapy.

[115]  K. Sowinski,et al.  Higher renal replacement therapy dose delivery influences on drug therapy. , 2003, Artificial organs.

[116]  P. Schollmeyer,et al.  Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients. , 1995, Clinical nephrology.

[117]  U. Maggiore,et al.  Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure , 2004, Critical care medicine.

[118]  N. Matsuda,et al.  Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration , 2003, Intensive Care Medicine.

[119]  J. Lipman,et al.  Continuous infusion ceftazidime in intensive care: a randomized controlled trial. , 1999, The Journal of antimicrobial chemotherapy.

[120]  K. Ikawa,et al.  Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration. , 2008, The Japanese journal of antibiotics.

[121]  L. Kaufman,et al.  Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection , 1991, Antimicrobial Agents and Chemotherapy.

[122]  K. Ikawa,et al.  Pharmacokinetics and pharmacodynamics of once-daily arbekacin during continuous venovenous hemodiafiltration in critically ill patients , 2009, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[123]  N. Pannu,et al.  An overview of drug-induced acute kidney injury , 2008, Critical care medicine.

[124]  W. Craig.  Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients , 1984, European Journal of Clinical Microbiology.

[125]  W. Craig,et al.  Kinetics of antimicrobial activity. , 1986, The Journal of pediatrics.

[126]  R. Mundkowski,et al.  Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous Hemodialysis , 2002, Antimicrobial Agents and Chemotherapy.

[127]  R. Boots,et al.  Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. , 2006, The Journal of antimicrobial chemotherapy.

[128]  S. Markantonis,et al.  A Pilot Study of Netilmicin Pharmacokinetics During Continuous Venovenous Hemodiafiltration , 2005, Journal of clinical pharmacology.

[129]  J. Schüttler,et al.  Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration , 1997, Antimicrobial agents and chemotherapy.

[130]  J. Paratz,et al.  Continuous infusion of β-lactam antibiotics in severe infections: a review of its role , 2007 .

[131]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[132]  K. Oh,et al.  Removal of Amikacin in Patients Undergoing Continuous Venovenous Hemodiafiltration , 2006 .

[133]  T. Golper.  Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. , 2001, Contributions to nephrology.

[134]  J. Camm,et al.  Cardiotoxicity of fluoroquinolones. , 2002, The Journal of antimicrobial chemotherapy.

[135]  Jerome J. Schentag.  Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. , 1999, Journal of chemotherapy.

[136]  C. Guinchard,et al.  Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. , 1998, Critical care medicine.

[137]  G. Bernard,et al.  Therapeutic intervention and targets for sepsis. , 2005, Annual review of medicine.

[138]  A. Chow,et al.  Safety and Pharmacokinetics of Multiple 750-Milligram Doses of Intravenous Levofloxacin in Healthy Volunteers , 2001, Antimicrobial Agents and Chemotherapy.

[139]  W. Macias,et al.  Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[140]  D. Nicolau,et al.  Pharmacodynamics of Intermittent- and Continuous-Infusion Cefepime Alone and in Combination with Once-Daily Tobramycin against Pseudomonas aeruginosa in an in vitro Infection Model , 1999, Chemotherapy.

[141]  M. Bonten,et al.  Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. , 2001, American journal of respiratory and critical care medicine.

[142]  B. Meyers,et al.  Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers , 1983, Antimicrobial Agents and Chemotherapy.

[143]  L. B. Hovde,et al.  Fluoroquinolone Resistance in Anaerobic Bacteria following Exposure to Levofloxacin, Trovafloxacin, and Sparfloxacin in an In Vitro Pharmacodynamic Model , 2001, Antimicrobial Agents and Chemotherapy.

[144]  G. Drusano,et al.  Multiple‐dose ciprofloxacin dose ranging and kinetics , 1985, Clinical pharmacology and therapeutics.

[145]  Daniel Parent,et al.  Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[146]  J. Scribante,et al.  Pharmacokinetic Profiles of High-Dose Intravenous Ciprofloxacin in Severe Sepsis , 1998, Antimicrobial Agents and Chemotherapy.

[147]  M. Churchwell,et al.  THE CLINICAL APPLICATION OF CRRT—CURRENT STATUS: Drug Dosing During Continuous Renal Replacement Therapy , 2009, Seminars in dialysis.

[148]  D. Farin,et al.  Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. , 2002, International journal of antimicrobial agents.

[149]  S. Mousdale,et al.  Ciprofloxacin levels in a patient undergoing veno-venous haemodiafiltration , 2005, Intensive Care Medicine.

[150]  Jonathan Cohen,et al.  The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit , 2005, Critical care medicine.

[151]  M. Churchwell,et al.  Daptomycin Clearance during Modeled Continuous Renal Replacement Therapy , 2006, Blood Purification.

[152]  J. Parrillo.  Pathogenetic mechanisms of septic shock. , 1993, The New England journal of medicine.

[153]  J. Korevaar,et al.  Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing , 2006, Intensive Care Medicine.

[154]  M. A. Marx,et al.  Drug dosing adjustments during continuous renal replacement therapies. , 1998, Kidney international. Supplement.

[155]  W. Couet,et al.  Norfloxacin-Induced Electroencephalogram Alteration and Seizures in Rats Are Not Triggered by Enhanced Levels of Intracerebral Glutamate , 2003, Antimicrobial Agents and Chemotherapy.

[156]  A. Dzierba,et al.  The Effects of Continuous Renal Replacement on Anti-infective Therapy in the Critically Ill , 2005 .

[157]  M. Honda,et al.  Pharmacokinetics of Imipenem and Cilastatin During Continuous Venovenous Hemodialysis in Patients Who Are Critically III , 1997, ASAIO journal.

[158]  R. Moore,et al.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.

[159]  P. Blankestijn,et al.  Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients , 1999, Intensive Care Medicine.

[160]  Jerome J. Schentag.  Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[161]  H. Hirasawa,et al.  Continuous hemofiltration/hemodiafiltration in critical care. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[162]  K. Ratheiser,et al.  Single-Dose Pharmacokinetics of Meropenem during Continuous Venovenous Hemofiltration , 1998, Antimicrobial Agents and Chemotherapy.

[163]  B. Zarowitz,et al.  Continuous Arteriovenous Hemofiltration of Aminoglycoside Antibiotics in Critically Ill Patients , 1986, Journal of clinical pharmacology.